Fight poison with poison, cure brain cancer with virus!

On November 1, Daiichi Sankyo announced that its oncolytic virus DELYTACT® (teserpaturev/G47∆)*1 jointly developed with Dr.
Tomoki Todo of the University of Tokyo’s Institute of Medical Sciences was officially launched in Japan and sold in designated hospitals.
Isankyo will establish a stable drug supply system as soon as possible
.

By then, the world's first oncolytic virus therapy approved for the treatment of primary brain tumors will officially debut! It is reported that in June of this year, the oncolytic virus therapy Delytact received conditionaland time-limited approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of malignant glioma.
On August 4, the Ministry of Health, Labour and Welfare of Japan will Oncolytic virus therapy Delytact is included in public medical insurance
.

Glioma is a common primary brain tumor, accounting for about 80% of all brain tumors
.

Glioma progresses rapidly, has a high recurrence rate, and has a poor prognosis.
The median survival time is less than 20 months, and the 5-year survival rate is only 5%.
There is an urgent need for more effective treatments
.

The emergence of oncolytic virus therapy Delytact has brought a new turn for the treatment of glioma
.

This is a third-generation oncolytic virus developed based on the herpes simplex virus (HSV-1).
It is also the world's first herpes virus drug to treat cancer through genetic modification of HSV-1
.

The researchers modified the HSV genome through genetic engineering to enhance the selective replication of Delytact in tumor cells, and while lysing tumor cells, it stimulates the human body's anti-tumor immune response, thereby enhancing the anti-tumor activity of the oncolytic virus
.

This means that Delytac can enhance the anti-tumor immune response while maintaining high safety
.

In other words, it is to use poison to fight the virus, and use the originally "toxic" virus to kill the "toxic" tumor
.

 According to relevant clinical statistics, the 1-year survival rate of the oncolytic virus therapy Delytact for malignant glioma is as high as 92.
3%, which is about 6 times that of conventional treatment, which significantly improves the survival rate of patients with malignant glioma
.

According to another review published by the Ministry of Health, Labour and Welfare of Japan, in addition to glioma, Delytact Japan is also studying its use in patients with metastatic tumors (including breast cancer, head and neck cancer, gastrointestinal cancer, and malignant melanoma.
) T-Vec, JX-594 for primary/metastatic liver tumors, CG0070 for bladder cancer, etc.
, are designed to allow more patients to benefit from oncolytic virus therapy
.

Prior to Delytact, there were three other oncolytic virus products on the global market, namely Rigvir from Latima Latima, Encore from Shanghai Sanwei Biotechnology Co.
, Ltd.
, and Imlygic (Talimogenelaherparepvec) from Biovex under Amgen
.

The prospects for the development of oncolytic viruses are obvious to all, and this kind of cancer treatment method of "attacking poison with poison" is becoming more and more popular among pharmaceutical companies
.

The launch of four oncolytic virus products has brought more confidence to other companies that develop oncolytic viruses.
At present, many domestic and foreign companies have deployed
.

There are nearly 200 oncolytic virus products under research worldwide
.

It is expected that more and more oncolytic virus products will be launched on the market, which will bring more diversified options for cancer treatment
.

End reference materials: [1]doi:10.
3960/jslrt.
21023[2]https://pharmaphorum.
com/news/first-launch-for-daiichi-sankyos-oncolytic-virus-delytact-in-japan/[3] http://